Evidence Framework
Health for Life is built on a simple commitment: we only recommend what is justified by evidence, appropriateness, and your context. This page explains how we decide what to offer, what to avoid, and how we keep that discipline visible.
Why Evidence Discipline Matters
The longevity and wellness market is crowded with tests, scans, and interventions whose benefits are uncertain, overstated, or dependent on very specific use cases. For high-performing people used to disciplined decision-making, that noise creates risk, not reassurance.
Our evidence framework exists to do three things:
Separate what is well-supported from what is speculative
Make clear when "more" (especially more testing) does not mean "better"
Show how each component of the programme contributes to managing your health trajectory over time
Evidence discipline is not a limitation. It is how we protect you from hype, unnecessary anxiety, incidental findings with unclear significance, and low-value care that creates activity without improving outcomes.
How We Grade Evidence
Every major element of the programme is mapped against recognised evidence standards and screening principles, rather than internal opinion or marketing logic. In practice this means:
We distinguish between strong evidence for benefit in defined groups, emerging evidence, and areas where data is limited or contested. Not all interventions or investigations have the same level of support. We are explicit about which category something falls into.
We are clear when something is included for safety versus long-term outcome improvement. For example, medical clearance before strenuous exercise testing exists to prevent harm during assessment, not because the clearance process itself extends healthspan.
We document why each investigation, intervention, or monitoring element is in the programme, and under what circumstances it is deferred or not recommended. This is governance, not guesswork.
We update our approach as evidence evolves. What we recommend today reflects the current state of the literature. If new trials or guidelines shift the evidence base, our protocols adjust accordingly.
What We Deliberately Avoid - and Why
Our aim is not to be comprehensive in what we offer, but precise in what we endorse. We therefore avoid several categories of investigation and intervention, even when competitors promote them heavily.
Saying "no" is part of how we protect you from unnecessary anxiety, incidental findings, and low-value care. Discipline creates trust, not limitation.
-
We do not offer whole-body MRI or CT scans as routine screening for asymptomatic individuals.
Why not: High rates of incidental findings (often benign but requiring follow-up), no demonstrated mortality benefit in asymptomatic populations, significant anxiety and cost burden from false positives. The UK National Screening Committee does not recommend whole-body imaging for general screening, and neither do we.
When we do use imaging: Targeted scans when clinical risk assessment indicates likely benefit. Details on our Imagingpage.
-
We do not offer interventions promoted primarily in the longevity space without adequate evidence of benefit in humans—this includes many off-label medications, peptides, and novel biologics.
Why not: Insufficient data on long-term safety and efficacy. Risk of harm often poorly characterised. High potential for placebo effect and confirmation bias in uncontrolled settings.
When we do use emerging interventions: Only when evidence reaches a threshold that justifies clinical use, and after transparent discussion of uncertainty with you.
-
Flexible, expert advice when you need it. Book hourly support across a range of topics—from planning to problem-solving. This focused consultation will help clarify your goals, map out next steps, and identify opportunities for growth.
-
We do not routinely offer polygenic risk scores, telomere length testing, or biological age clocks as part of standard assessment.
Why not: Limited evidence that these tests improve clinical decision-making or outcomes. Results are often difficult to interpret and may create unwarranted anxiety or false reassurance. Where family history or clinical presentation suggests monogenic risk (e.g., familial hypercholesterolaemia, BRCA mutations), targeted genetic testing may be appropriate and will be discussed.
When we do consider genetic testing: When results are likely to be actionable and the test meets clinical validity and utility criteria.
How This Shapes Your Programme
The evidence framework is applied at three levels within your programme:
Foundational Assessment
Investigations are chosen to answer specific clinical questions—particularly around safety for structured exercise, cardiovascular risk stratification, and major preventable disease screening. They are not bundled to create an impressive list or because competitors include them.
If an investigation does not meet our appropriateness criteria for your individual risk profile, it is not included, even if you request it. If you disagree, we will explain our reasoning and, where appropriate, document your informed decision to proceed outside our standard protocol.
Ongoing Management
Metrics are selected because they track trajectory and inform decisions, not because they are fashionable or easy to measure. We focus on leading indicators—particularly physical capacity—that predict long-term outcomes, rather than optimising isolated numbers that may not translate to better health.
When biomarkers or other measures are repeated, it is because the result will influence your plan. We do not re-test for reassurance.
Programme Evolution
We evaluate outcomes at programme level using aggregated, anonymised data. This allows us to assess whether our protocols are producing the expected effects, refine our approach where evidence or results suggest adjustment, and strengthen clinical governance over time.
The evidence framework is therefore not static. It evolves as the literature develops and as we learn from the outcomes we observe.
Where to Find the Details
We have documented our approach to the major domains of assessment and monitoring. Each page explains what we do, when we do it, and why—as well as what we deliberately do not offer.
Laboratory Tests
Which biomarker panels we use, what clinical questions they answer, and what we don't routinely test (with rationale). Includes our approach to cardiovascular, hormone, nutritional, and cancer screening biomarkers.
Imaging
Our appropriateness criteria for scans, who receives which imaging modality and why, and what we don't routinely offer (including whole-body MRI and CT). Explains how we balance detection benefit against false-positive burden.
Exercise Capacity Assessment
How we measure strength, cardiovascular fitness, and movement quality, and why physical capacity is central to outcome measurement. Includes safety protocols and progression principles.
This is not marketing. This is governance made visible.
If you want your health managed by a team that can explain not just what they recommend, but why it meets a defined evidential standard, we should talk.
How to Get Started
Ready to join the wait list?
Want to learn more first?
Explore the Programme | How It Works | Membership & Fees | Outcomes